About that, mechanisms relies on Homeobox-type transcription factors overexpressed during the embryonic segmentation and differentiation of mesenchymal layers, such as Mesenchyme Homeobox-2 factor, have been detected controlling to the GLI-1 gene expression at gene promoter level, promoting lung oncology therapy resistance capacity, and also been associated with progression, global survival and response capacity to therapy in lung cancer patients [133]. The gene discussed is GLI1; the disease is lung carcinoma.